

21957



0440

0300

0420 9500

0420

IN THE U.S. PATENT AND TRADEMARK OFFICE

Inventor                   Saul TZIPORI et al  
Patent App.               10/041,958  
Filed                      7 January 2002  
For                        HEMOLYTIC UREMIC SYNDROME  
Art Unit                   Not known  
Hon. Commissioner of Patents  
Washington, DC 20231

**PRELIMINARY AMENDMENT**

Prior to examination of the above-identified application,  
please amend as follows:

**IN THE SPECIFICATION**

Please replace page 1 of the specification with revised  
page 1 enclosed herewith.

Respectfully submitted,  
The Firm of Karl F. Ross P.C.

  
\_\_\_\_\_  
Jonathan Myers, Reg. No. 26,963  
Attorney for Applicant

er  
24 January 2002  
5676 Riverdale Avenue Box 900  
Bronx, NY 10471-0900  
Cust. No.: 535  
Tel: (718) 884-6600  
Fax: (718) 601-1099

Enclosure: Revised Specification Page 1

**HUMAN NEUTRALIZING ANTIBODIES AGAINST HEMOLYTIC UREMIC SYNDROME****SPECIFICATION****CROSS REFERENCE TO RELATED APPLICATION**

This application is a continuation-in-part of copending  
5 application 09/302,125 filed 29 April 1999 which is a division of  
application 08/749,704 filed 15 November 1996, now abandoned.

**STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT**

This invention was made with government support under  
10 AI41326 and DK58993 awarded by the National Institutes of Health.  
The government has certain rights in the invention.

**FIELD OF THE INVENTION**

The present invention relates to new human monoclonal  
15 antibodies capable of neutralizing Shiga or Shiga-like toxins  
which cause hemolytic uremic syndrome in mammals, a process for  
the preparation of the new human monoclonal antibodies and a  
method of treating a mammalian subject to prevent the development  
of hemolytic uremic syndrome in a mammalian subject by  
administering the monoclonal antibodies to the subject. More  
particularly the invention relates to human monoclonal antibodies  
20 prepared by administering as an antigen to a transgenic mouse  
having human genes an inactivated Shiga-like toxin to induce an  
immune response, isolating a splenocyte from the transgenic  
mouse, fusing the splenocyte to a mouse myeloma cell to form a  
hybridoma, and screening human monoclonal antibodies produced by  
25 the hybridoma for the ability to neutralize Shiga or Shiga-like  
toxins.